At Asklepios BioPharmaceutical (AskBio), we are making history with every clinical advancement and aspire to turn hope into cures by unravelling new possibilities for genetic medicine. We became a wholly owned, independently operated subsidiary of Bayer AG in late 2020 as a cornerstone of its newly formed Cell & Gene Therapy Platform.
AskBio is headquartered in North Carolina, and has additional research and development facilities in Paris, France (formerly BrainVectis), Edinburgh, Scotland and gene therapy manufacturing in San Sebastian, Spain.
Started in 2001, we are on a never-ending quest to advance genetic technology and life-saving gene therapy. We are singularly focused on a goal to erase genetic disease. It is an audacious goal that will not be accomplished by us alone, but it is one to which we have already made significant contributions.